Treatment-Naïve
Dyslipidemia in Treatment Naïve HIV
... DYSLIPIDEMIA IN TREATMENT NAÏVE HIV INTRODUCTION ABSTRACT The natural history of human immunodeficiency virus HIV infection changes with the use of highly active antiretroviral therapy H[r] ...
132
Cryptococcal Antigenaemia among Treatment Naïve Adult HIV Infected Nigerian Patients
... among treatment naïve HIV positive Nigerian ...among treatment naïve HIV positive patients is comparable with previous reports from Shika in Nigeria ...
7
Naturally occurring mutations to HCV protease inhibitors in treatment naïve patients
... 15. Thompson AJ, McHutchison JG: Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009, 16:377 – 387. 16. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, ...
8
Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study
... In this study prevalence of anemia in HAART naïve patients was 29.7% and on those patients on HAART was 11.7%. This indicates that prevalence of anemia is higher in treatment naïve patients (P < ...
7
Progression of Platelet Counts in Treatment Naïve HIV/HCV Co Infection
... HIV treatment naive patients from four sites in the Centers for AIDS Research Network of Inte- grated Clinical Systems (CNICS) cohort with platelet count measurements between 2002 and ...of treatment for ...
5
Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study
... were treatment-naïve, and only 12 treatment-naïve patients received DEX implant alone versus with other ...that treatment with DEX im- plant alone can be effective as initial therapy ...
7
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials
... A total of 6319 studies were identified from the original lit- erature (Additional file 1). After screening the titles and ab- stracts, 1040 potentially relevant publications were retrieved for full text review (kappa = ...
15
Raltegravir in treatment naïve patients
... the treatment of HIV ...for naïve pa- ...line treatment is certainly pre- dictable. In naïve patients, raltegravir has demonstrated mid- and long-term efficacy in reducing HIV-RNA to < 50 ...
8
The GOLMePsA study protocol: an investigator initiated, double blind, parallel group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes
... To date, there are no data on the role of WB-MRI as an outcome measure in PsA. Further, the use of bDMARDs on treatment naïve, early diagnosed PsA patients has not been addressed in double blind randomized ...
13
Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients
... of treatment-naïve and previously treated patients who were taking systemic β -blockers was simi- lar in the FCBT PF ...in treatment- naïve patients, compared with previously treated ...
7
Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
... the treatment impact of combination therapy in the FC II participants was numerically greater as com- pared to those with FC III symptoms ...median treatment exposure of 76 weeks, there were no PAH-related ...
10
Gemcitabine and Carboplatin in Inoperable, Loco- Regionally Advanced and Metastatic Gallbladder Cancer- A Study from Northern Indian Cancer Institute
... Carboplatin is an analog of cisplatin and when administered alone or in combination therapy has shown lower nephro and neurotoxicity as compared to cisplatin [19]. Further, carboplatin offers the possibility of ...
7
<p>Demographic, Clinical and Management Characteristics of Newly Diagnosed COPD Patients in Turkey: A Real-Life Study</p>
... To our knowledge, this is the fi rst prospective real-life study on newly diagnosed and treatment-naïve COPD patients. Although these patients were diagnosed for the fi rst time, the GOLD C and D categories ...
7
Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
... C treatment has continued to evolve, and interferon-free, oral treatment with direct-acting antiviral agents is the current standard of ...new treatment, which is a combination of two direct-acting ...
12
A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir
... on treatment naïve and treatment experienced patients with chronic HCV genotype 4, including cirrhotics and non ...cirrhotics. Naïve (cirrhotics and non cirrhotics) and relapsers non ...
7
Increased microRNA 155 expression in the serum and peripheral monocytes in chronic HCV infection
... that treatment-naïve patients with chronic HCV infec- tion have increased expression of miR-155 in their circu- lating monocytes that are the major sources of TNFα ...
10
Raltegravir, elvitegravir, and metoogravir: the birth of "me too" HIV 1 integrase inhibitors
... term treatment in dogs, bringing a premature end to the drug's clinical progress ...both treatment-experienced and treatment-naïve patients [32], MK-0518 has exhibited low nanomolar and strand ...
14
<p>Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US</p>
... in treatment-naïve mMCC patients and £35,274 in treatment-experienced ...for treatment-experi- enced and treatment-naïve patients, ...1L treatment of avelumab in mMCC ...
11
Outcome of Sofosbuvir and Ribavirin based treatment in genotype 3 of cirrhotic chronic hepatitis C patients
... among treatment naïve patients (n=94) who received sofosbuvir and ribavirin for twenty four weeks sustained virological response was achieved by 58%, while as in treatment experienced patients (n=88) ...
5
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
... 3 mg/dL, international normalized ratio 2.3, and serum alpha-fetoprotein level 100 ng/mL. Three hundred and eighty patients were randomized to receive open-label PrOD plus RBV for 12 or 24 weeks. Compared to the ...
12